CD74

Gene

CD74 molecule

HGNCHGNC:1697 EnsemblENSG00000019582 NCBI Gene972

Locus: gene with protein productLocation: 5q33.1

Encodes

via encodes

The protein product this gene encodes, reached through the canonical GENE→PROTEIN (encodes) relation. Its biology, drugs, indications, trials and therapeutic evidence live on the protein's own page.

HLA class II histocompatibility antigen gamma chainP04233

Protein · therapeutic target

Clinically validated target · 1 approved medicine against this target

Explore protein biology & therapeutics

Also known as

Symbols and names change; identity (the HGNC ID) does not. Previous and alternative forms are kept distinct.

Also known asDHLAG · CLIP

View full nomenclature history (9)

Previous symbolsDHLAG

Alias symbolsCLIP

Previous namesCD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated), CD74 molecule, major histocompatibility complex, class II invariant chain

Alias namesHLA-DR-gamma, Ia-associated invariant chain, gamma chain of class II antigens, MHC HLA-DR gamma chain, class II MHC-associated invariant chain peptide

Associated diseases

via associated_with

Diseases linked to this gene through the canonical GENE→DISEASE (associated_with) relation, drawn from Open Targets' top-ranked associations by overall score — not the full association set. Disease-level detail lives on each disease's own page.

Carcinoma, Non-Small-Cell Lung

Neoplasms

Adenocarcinoma of Lung

Squamous cell lung carcinoma

Lymphoid neoplasm

Acinar lung adenocarcinoma

Breast Neoplasms

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Myeloid, Acute

Drawn from Open Targets’ top 10 associations by overall score for this gene — the subset resolved to a canonical disease. Lower-ranked associations, and diseases not yet canonicalised, are not shown.

Gene family

HGNC gene-group membership.

CD molecules

Provenance

HGNCCanonical human gene identity from HGNC (release 2026-07-07), updated 2023-01-20.

Open TargetsGene–disease associations from the Open Targets Platform.